Seres Therapeutics (MCRB) Misses Q1 EPS by 2c

Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update

SER-109 Phase 2 study enrollment complete; results expected in mid-2016

Academic collaborations further microbiome therapeutic leadership in immuno-oncology, rare genetic diseases and other indications

$120 million upfront payment obtained from Nestlé Health Science

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today reported first quarter 2016 financial results and provided an operational progress update.

The first quarter was marked by strong progress extending our leadership position in the development of microbiome therapeutics, said... More

Seres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice President

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics company, announced today that it has appointed Thomas J. DesRosier as Chief Legal Officer and Executive Vice President. DesRosier will be responsible for global legal operations, as well as corporate compliance and quality assurance. He will also act as Secretary for Seres Leadership Team and its Board of Directors.

Tom is a highly seasoned, proven biopharma leader who will strengthen our leadership team at a crucial stage in our growth and development, said Roger Pomerantz, M.D., President, Chief Executive... More